Guangdong Jiaying Pharmaceutical Co Ltd
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablet… Read more
Guangdong Jiaying Pharmaceutical Co Ltd (002198) - Total Assets
Latest total assets as of September 2025: CN¥774.73 Million CNY
Based on the latest financial reports, Guangdong Jiaying Pharmaceutical Co Ltd (002198) holds total assets worth CN¥774.73 Million CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guangdong Jiaying Pharmaceutical Co Ltd - Total Assets Trend (2004–2024)
This chart illustrates how Guangdong Jiaying Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guangdong Jiaying Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangdong Jiaying Pharmaceutical Co Ltd's total assets of CN¥774.73 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 40.1% |
| Accounts Receivable | CN¥130.09 Million | 15.5% |
| Inventory | CN¥85.06 Million | 10.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥45.89 Million | 5.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Guangdong Jiaying Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Jiaying Pharmaceutical Co Ltd's current assets represent 66.0% of total assets in 2024, an increase from 25.1% in 2004.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2024, up from 3.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 8.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Guangdong Jiaying Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Guangdong Jiaying Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Guangdong Jiaying Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Guangdong Jiaying Pharmaceutical Co Ltd generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Guangdong Jiaying Pharmaceutical Co Ltd generates $ 2.46 in net profit.
Guangdong Jiaying Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.15 | 25.41 | 4.80 |
| Quick Ratio | 12.38 | 21.14 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥435.34 Million | CN¥ 498.20 Million | CN¥ 344.06 Million |
Guangdong Jiaying Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong Jiaying Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.10 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | -1.0% |
| Total Assets | CN¥838.82 Million |
| Market Capitalization | $459.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Jiaying Pharmaceutical Co Ltd's assets below their book value (0.55 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Guangdong Jiaying Pharmaceutical Co Ltd's assets decreased by 1.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Guangdong Jiaying Pharmaceutical Co Ltd (2004–2024)
The table below shows the annual total assets of Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥838.82 Million | -1.03% |
| 2023-12-31 | CN¥847.56 Million | +0.11% |
| 2022-12-31 | CN¥846.65 Million | +4.87% |
| 2021-12-31 | CN¥807.34 Million | -0.14% |
| 2020-12-31 | CN¥808.44 Million | -5.55% |
| 2019-12-31 | CN¥855.94 Million | -3.78% |
| 2018-12-31 | CN¥889.56 Million | +1.48% |
| 2017-12-31 | CN¥876.61 Million | -20.25% |
| 2016-12-31 | CN¥1.10 Billion | +4.89% |
| 2015-12-31 | CN¥1.05 Billion | +1.23% |
| 2014-12-31 | CN¥1.04 Billion | +12.65% |
| 2013-12-31 | CN¥919.00 Million | +192.45% |
| 2012-12-31 | CN¥314.25 Million | +2.51% |
| 2011-12-31 | CN¥306.55 Million | +1.89% |
| 2010-12-31 | CN¥300.87 Million | +18.77% |
| 2009-12-31 | CN¥253.33 Million | +7.69% |
| 2008-12-31 | CN¥235.24 Million | -4.17% |
| 2007-12-31 | CN¥245.48 Million | +104.48% |
| 2006-12-31 | CN¥120.05 Million | +31.59% |
| 2005-12-31 | CN¥91.23 Million | +26.85% |
| 2004-12-31 | CN¥71.92 Million | -- |